Erwin F Wagner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1375718/publications.pdf

Version: 2024-02-01

53751 74108 14,225 77 45 75 citations h-index g-index papers 80 80 80 21963 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	TPL-2 Inhibits IFN- $\hat{1}^2$ Expression via an ERK1/2-TCF-FOS Axis in TLR4-Stimulated Macrophages. Journal of Immunology, 2022, 208, 941-954.	0.4	3
2	An immune-sympathetic neuron communication axis guides adipose tissue browning in cancer-associated cachexia. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119 , .	3.3	28
3	Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease. Annals of the Rheumatic Diseases, 2022, 81, 1400-1408.	0.5	11
4	In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun. Oncogene, 2021, 40, 2437-2447.	2.6	21
5	Psoriatic skin inflammation is promoted by câ€Jun/APâ€1â€dependent CCL2 and ILâ€23 expression in dendritic cells. EMBO Molecular Medicine, 2021, 13, e12409.	3.3	42
6	The AP-1 transcription factors c-Jun and JunB are essential for CD8 \hat{l}_{\pm} conventional dendritic cell identity. Cell Death and Differentiation, 2021, 28, 2404-2420.	5.0	18
7	Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model. Experimental Dermatology, 2021, 30, 1662-1674.	1.4	16
8	JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia, 2021, 35, 3509-3525.	3.3	19
9	Calprotectin: from biomarker to biological function. Gut, 2021, 70, 1978-1988.	6.1	163
10	Sequestosome 1/p62 enhances chronic skin inflammation. Journal of Allergy and Clinical Immunology, 2021, 147, 2386-2393.e4.	1.5	10
11	Syndecan-1 shedding by meprin \hat{l}^2 impairs keratinocyte adhesion and differentiation in hyperkeratosis. Matrix Biology, 2021, 102, 37-69.	1.5	6
12	Targeting AP-1 transcription factors by CRISPR in the prostate. Oncotarget, 2021, 12, 1956-1961.	0.8	11
13	Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment. Cancer Research, 2021, 81, 968-985.	0.4	27
14	Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity. Blood, 2021, 138, 2644-2644.	0.6	0
15	Wnt signaling and Loxl2 promote aggressive osteosarcoma. Cell Research, 2020, 30, 885-901.	5.7	68
16	Cutaneous Immune Cell-Microbiota Interactions Are Controlled by Epidermal JunB/AP-1. Cell Reports, 2019, 29, 844-859.e3.	2.9	13
17	Role of bulge epidermal stem cells and <scp>TSLP</scp> signaling in psoriasis. EMBO Molecular Medicine, 2019, 11, e10697.	3.3	17
18	Fra-2–expressing macrophages promote lung fibrosis. Journal of Clinical Investigation, 2019, 129, 3293-3309.	3.9	67

#	Article	IF	CITATIONS
19	Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis. Blood, 2019, 134, 4341-4341.	0.6	O
20	Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy. Blood, 2019, 134, 4415-4415.	0.6	0
21	Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration. Journal of Visualized Experiments, 2018, , .	0.2	8
22	EGFR is required for FOSâ€dependent bone tumor development via RSK2/CREB signaling. EMBO Molecular Medicine, 2018, 10, .	3.3	24
23	Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. Journal of Experimental Medicine, 2017, 214, 1387-1409.	4.2	80
24	Chronic systemic inflammation originating from epithelial tissues. FEBS Journal, 2017, 284, 505-516.	2.2	19
25	Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes and Development, 2016, 30, 489-501.	2.7	239
26	Chronic skin inflammation leads to bone loss by IL-17–mediated inhibition of Wnt signaling in osteoblasts. Science Translational Medicine, 2016, 8, 330ra37.	5.8	133
27	Role of IL-17A signalling in psoriasis and associated bone loss. Clinical and Experimental Rheumatology, 2016, 34, 17-20.	0.4	23
28	A waste of insulin interference. Nature, 2015, 521, 430-431.	13.7	34
29	Signalling in inflammatory skin disease by AP-1 (Fos/Jun). Clinical and Experimental Rheumatology, 2015, 33, S44-9.	0.4	25
30	Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17582-17587.	3.3	45
31	Specific roles for dendritic cell subsets during initiation and progression of psoriasis. EMBO Molecular Medicine, 2014, 6, 1312-1327.	3.3	92
32	Targeting <i>miR-21</i> to Treat Psoriasis. Science Translational Medicine, 2014, 6, 225re1.	5.8	123
33	Regulation of Steatohepatitis and PPARÎ ³ Signaling by Distinct AP-1 Dimers. Cell Metabolism, 2014, 19, 84-95.	7.2	99
34	Inhibition of De Novo NAD + Synthesis by Oncogenic URI Causes Liver Tumorigenesis through DNA Damage. Cancer Cell, 2014, 26, 826-839.	7.7	162
35	A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia. Cell Metabolism, 2014, 20, 433-447.	7.2	535
36	Activator protein 1 transcription factor fos-related antigen 1 (fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. Hepatology, 2014, 59, 261-273.	3.6	25

#	Article	IF	CITATIONS
37	Inflammation-mediated skin tumorigenesis induced by epidermal c-Fos. Genes and Development, 2013, 27, 1959-1973.	2.7	53
38	S100A8-S100A9 Protein Complex Mediates Psoriasis by Regulating the Expression of Complement Factor C3. Immunity, 2013, 39, 1171-1181.	6.6	205
39	Mouse models for liver cancer. Molecular Oncology, 2013, 7, 206-223.	2.1	144
40	JUNB/AP-1 controls IFN-Î ³ during inflammatory liver disease. Journal of Clinical Investigation, 2013, 123, 5258-5268.	3.9	44
41	A Validated Regulatory Network for Th17 Cell Specification. Cell, 2012, 151, 289-303.	13.5	1,010
42	Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nature Cell Biology, 2012, 14, 1203-1211.	4.6	218
43	Psoriasis: what we have learned from mouse models. Nature Reviews Rheumatology, 2010, 6, 704-714.	3.5	190
44	Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21264-21269.	3.3	135
45	Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20423-20428.	3.3	58
46	Signal integration by JNK and p38 MAPK pathways in cancer development. Nature Reviews Cancer, 2009, 9, 537-549.	12.8	2,122
47	Epidermal JunB represses G-CSF transcription and affects haematopoiesis and bone formation. Nature Cell Biology, 2008, 10, 1003-1011.	4.6	41
48	c-Jun Controls Histone Modifications, NF-κB Recruitment, and RNA Polymerase II Function To Activate the <i>ccl2</i> Gene. Molecular and Cellular Biology, 2008, 28, 4407-4423.	1.1	83
49	Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10525-10530.	3.3	163
50	Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17105-17110.	3.3	64
51	NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1. Journal of Biological Chemistry, 2007, 282, 18245-18253.	1.6	364
52	Role of heterodimerization of c-Fos and Fra1 proteins in osteoclast differentiation. Bone, 2007, 40, 867-875.	1.4	26
53	Simultaneous generation of <i>fra</i> â€2 conditional and <i>fra</i> â€2 knockâ€out mice. Genesis, 2007, 45, 447-451.	0.8	23
54	p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway. Nature Genetics, 2007, 39, 741-749.	9.4	342

#	Article	IF	Citations
55	Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. International Journal of Biochemistry and Cell Biology, 2006, 38, 1043-1049.	1.2	131
56	Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature, 2005, 437, 369-375.	13.7	538
57	Fos and Jun Proteins Are Specifically Expressed During Differentiation of Human Keratinocytes. Journal of Investigative Dermatology, 2005, 124, 212-220.	0.3	109
58	Fos/AP-1 proteins in bone and the immune system. Immunological Reviews, 2005, 208, 126-140.	2.8	457
59	Essential role of RSK2 in c-Fos–dependent osteosarcoma development. Journal of Clinical Investigation, 2005, 115, 664-672.	3.9	81
60	Essential role of RSK2 in c-Fos–dependent osteosarcoma development. Journal of Clinical Investigation, 2005, 115, 664-672.	3.9	45
61	Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. Journal of Cell Biology, 2004, 164, 613-623.	2.3	188
62	JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells. Cell, 2004, 119, 431-443.	13.5	384
63	Rhabdomyosarcoma development in mice lacking Trp53 and Fos. Cancer Cell, 2003, 4, 477-482.	7.7	68
64	AP-1: a double-edged sword in tumorigenesis. Nature Reviews Cancer, 2003, 3, 859-868.	12.8	1,867
65	Liver Tumor Development. Cell, 2003, 112, 181-192.	13.5	445
66	Impaired Long-Term Memory and NR2A-Type NMDA Receptor-Dependent Synaptic Plasticity in Mice Lacking c-Fos in the CNS. Journal of Neuroscience, 2003, 23, 9116-9122.	1.7	321
67	Promoter Specificity and Biological Activity of Tethered AP-1 Dimers. Molecular and Cellular Biology, 2002, 22, 4952-4964.	1.1	171
68	Fra-1 substitutes for c-Fos in AP-1-mediated signal transduction in retinal apoptosis. Journal of Neurochemistry, 2002, 80, 1089-1094.	2.1	27
69	JunB can substitute for Jun in mouse development and cell proliferation. Nature Genetics, 2002, 30, 158-166.	9.4	132
70	Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO Journal, 2002, 21, 1782-1790.	3.5	234
71	Chronic Myeloid Leukemia with Increased Granulocyte Progenitors in Mice Lacking JunB Expression in the Myeloid Lineage. Cell, 2001, 104, 21-32.	13.5	215
72	C-Jun Nh2-Terminal Kinase (Jnk)1 and Jnk2 Have Similar and Stage-Dependent Roles in Regulating T Cell Apoptosis and Proliferation. Journal of Experimental Medicine, 2001, 193, 317-328.	4.2	199

ERWIN F WAGNER

#	Article	IF	CITATIONS
73	Protective Role of Raf-1 in Salmonella-Induced Macrophage Apoptosis. Journal of Experimental Medicine, 2001, 193, 353-364.	4.2	59
74	Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nature Genetics, 2000, 24, 184-187.	9.4	447
75	Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nature Medicine, 1999, 5, 314-319.	15.2	348
76	JunB is essential for mammalian placentation. EMBO Journal, 1999, 18, 934-948.	3.5	232
77	Stable murine chondrogenic cell lines derived from c- <i>fos</i> induced cartilage tumors. Journal of Bone and Mineral Research, 1993, 8, 839-847.	3.1	35